Tech Company Financing Transactions
Stellular Bio Funding Round
On 1/28/2026, Stellular Bio landed Series A investment from Ziff Capital Partners and Cockrell Interests.
Transaction Overview
Company Name
Announced On
1/28/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Ziff Capital Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead candidate, STLR-201, into clinical testing as a treatment for Sjogren's disease dry eye.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
65 Grove St 303
Watertown, MA 02472
US
Watertown, MA 02472
US
Phone
Website
Email Address
Overview
We aim to improve the lives of patients with ocular surface disease (OSD) with our pioneering platelet-derived regenerative biologic (PRB) therapy. Stellular has proven the efficacy of PRB in animal models and has established scalable manufacturing methods that will enable clinical trials and commercial production. We are pursuing initial clinical proof of concept in Sjogren's syndrome-related dry eye and are poised to expand rapidly into the broader OSD market.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Derek Adams
Chief Technical Officer
Li Malmberg
Co-Founder
Joseph Italiano
Browse more venture capital transactions:
Prev: 1/28/2026: Datatruck venture capital transaction
Next: 1/28/2026: The Realest venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs